New Funding Opportunity for Drug Development ProjectsContinue reading→

The Flinn Foundation Seed Grants to Promote Translational Research program has awarded a combined $1 million to 10 Arizona research teams with the potential to turn their findings into viable products and treatments that impact patients. The program’s 10^th cohort was selected in an open competitive process among 82 proposals from 13 universities, health systems, and research institutes — an increase from last year’s 73 applications.Continue reading→

Each year JPM Week brings together health innovators and investors to refresh or make the connections that drive health Invaton Forward Faster.  See where thy are in the spotlight this week.Continue reading→

Evolutionary Cell Biology is a new emerging subdiscipline that strives to integrate the fields of cell biology, biophysics, bioenergetics, and evolutionary theory in novel ways, in an attempt to develop a more comprehensive field of evolutionary biology focused at the mechanistic level. Thanks to a grant from the National Science Foundation, the public can listen in to this series of lectures via Zoom free of charge.Continue reading→

Pioneering a Novel Disease-Modifying Therapy for Obstructive Lung DiseaseContinue reading→

PHOENIX, AZ (January 8, 2025) – The Phoenix Bioscience Core (PBC) is proud to announce the launch of Investor Corner PBC — a dedicated space for investors to connect with innovators, entrepreneurs, and changemakers in the heart of Arizona’s bioscience ecosystem.Continue reading→

Securing capital for your startup can seem daunting to entrepreneurs, but with the right strategies, resources, and expert guidance, it’s entirely within reach. The Center for Entrepreneurial Innovation (CEI) has introduced Capital Cure, a 16-week course designed to guide you through the entire capital-raising process. Whether preparing for your first funding round or gearing up for future investment opportunities, this program will give you the tools and knowledge you need to succeed.Continue reading→

It’s a new year filled with opportunities as Arizona continues its drive to rise in the national life science rankings. Continue reading→

In the closing weeks of 2024, the Corporate Transparency Act (the CTA) has been making its way through the federal legal system creating a confusing on again-off again scenario.  (Read more at The National Law Review) On December 31, 2024, the U.S. Solicitor General went to the Supreme Court and filed an Application for a Stay of the Injunction issued by the United States District Court for the Eastern District of Texas (Application) in the case of Texas Top Cop Shop, et al. v. Garland, et al., appealing the initial nationwide injunction issued by the District Court against enforcement of the Corporate Transparency Act (CTA) and the ensuing conflicting appellate rulings by and within the U.S. Fifth Circuit Court of Appeals’ “motions panel” and “merits panel.”

What this means is the the future of the CTA still not resolved.

According to FinCEN on January 2, 2025, “In light of a recent federal court order, reporting companies are not currently required to file beneficial ownership information with FinCEN and are not subject to liability if they fail to do so while the order remains in force. However, reporting companies may continue to voluntarily submit beneficial ownership information reports.” SOURCE

Continue reading→